All In MedTech

FDA Clearance Tracker · P150035-S007

AVEIR™ Patient Transmitter, AVEIR™ Patient Transmitter Software, AVEIR™ Patient Trasmitter Wired Electrodes, Merlin.net™

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 11, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 11, 2024

Approved

Time to decision

241 days

Received Feb 13, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150035-S007
Device name
AVEIR™ Patient Transmitter, AVEIR™ Patient Transmitter Software, AVEIR™ Patient Trasmitter Wired Electrodes, Merlin.net™
Applicant location
Sylmar, CA
Received
Feb 13, 2024
Decided
Oct 11, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P150035

Device type

Device class
Class III
Regulation
21 CFR 870.3610

Every decision under product code PNJ

FDA's approval statement

As written in FDA's record.

Approval for the AVEIR™ Remote Care System designed to provide remote monitoring support for patients implanted with an Aveir Leadless Pacemaker(s).

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.